)
)
)
Rakuten Medical is a clinical and commercial-stage biotech advancing its Alluminox™ photoimmunotherapy platform, which combines a drug and device to treat cancers. Its lead asset, ASP-1929, an EGFR-targeted antibody-dye conjugate, is in a global Phase 3 trial with anti-PD-1 therapy and has been approved in Japan since 2021 for unresectable or recurrent head and neck cancer, with 800+ commercial treatments completed. In December 2024, the company enrolled the first patient in its global Phase 3 1L study, following strong ASCO 2024 data (24-month OS 52.4%, CR 23.5%, with a well-tolerated safety profile). Real-world post-marketing data further confirm efficacy and safety. Rakuten Medical is seeking partners to license and co-develop its technology globally.
Year Founded
2010
Next catalyst (value inflection) update
Interim analysis from ongoing global phase 3 trial for ASP1929 + anti-PD1 in 1st line, recurrent head and neck cancer
Expected time of next catalyst update
Mar-26
City
San Diego
Country
United States
Company CEO or top company official
Mickey Mikitani, CEO Minami Maeda, President Abhijit Bhatia, COO
Development Phase of Primary Product
Phase III
Lead Product in Development
ASP-1929
Number of Unlicensed Products
3
Therapeutic Area
Oncology
Website
https://rakuten-med.com/us/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
